NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The Global Immunology Market size is estimated to grow by USD 65.8 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 9.45% during the forecast period. Growing organ transplantation is driving market growth, with a trend towards significant pipeline of immunology However, entry of biosimilars poses a challenge - Key market players include 3SBio Inc.
, AbbVie Inc., Amgen Inc., ANTARES PHARMA INC.
, Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb Co.
, Eli Lilly and Co., F. Hoffmann La Roche Ltd.
, GlaxoSmithKline Plc, Horizon Therapeutics Plc, ImmuNext Inc., Incyte Corp., Johnson and Johnson Services Inc.
, Merck KGaA, Mitsubishi Chemical Group Corp., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co.
Ltd., and UCB SA. AI-Powered Market Evolution Insights.
Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now Key Market Trends Fueling Growth The global immunology market is set to experience significant growth due to the advancement of numerous promising immunological agents in various clinical trial stages. As of October 2021 , approximately 51 molecules are under development, with 22 in Phase II, four in Phase III, 16 in Phase I, and the remaining in Phase I/II trials. Notable developments include risankizumab (SKYRIZI) from AbbVie Inc.
, which is undergoing approval pro.